Drug Target Review

JUNE 11, 2025

Drug development is plagued by complex challenges, but multimodal AI is unlocking new opportunities. By integrating diverse data sources – from genomics to clinical insights – this approach is accelerating drug discovery, improving patient stratification and boosting success rates. Highlighting data integration.

Drugs

Drug Target Review

JUNE 9, 2025

A personal journey to Alltrna Michelle Werner’s career has spanned over 20 years in the pharmaceutical industry, where she developed her expertise in oncology drug development at leading companies such as Bristol Myers Squibb, AstraZeneca, and Novartis.

Disease

Drug Target Review

JUNE 16, 2025

By complementing traditional analytical methods, it provides a more accurate representation of drug behaviour to support translational and pre-clinical studies. This article explores the principles, applications and future potential of MSI in drug development. Drug Metab. 2024, 52 (11), 1181–1186. Mass Spectrom.

Drugs

Fierce BioTech

NOVEMBER 22, 2024

AI in Pharma: Benefits, Risks and the Road Ahead AI is revolutionizing the drug development process, streamlining and accelerating every stage, from research to approval and marketing. This whitepaper explores the benefits and risks of AI in the pharmaceutical industry and examines its future.

Drug Development

Alta Sciences

JUNE 6, 2025

For a contract research organization (CRO), it can play an integral role in increasing the quality and speed of drug development while reducing costs, repetitive manual tasks, and human error. About the Author Martin Rougée joined Altasciences in early 2024 as an Optimization Scientist. Do you need a pharmacokinetic study?

Pharmacokinetics

FDA Law Blog: Drug Discovery

JANUARY 30, 2025

Valentine We recently blogged about a new December 2024 draft guidance about accelerated approval (the December 2024 draft guidance). While the first topic is addressed primarily in the December 2024 draft guidance, the considerations and policies FDA articulates in the January 2025 draft guidance are also relevant.

FDA

Drug Target Review

DECEMBER 9, 2024

The 2024 Nobel Prize in Chemistry was awarded to Demis Hassabis and John Jumper from Google DeepMind for developing AlphaFold2, and to David Baker from the University of Washington for his work in computational protein design. These innovations have revolutionised the understanding of protein structures using artificial intelligence.

Engineering

Drug Target Review

AUGUST 6, 2025

The approach could offer a new angle on a disease that has thus far resisted most conventional drug development strategies. Meet Stephen Pinkosky Stephen Pinkosky, PhD, has served as Vice President of Drug Discovery and Development at Esperion since August 2024.

Therapies

Drug Target Review

JULY 7, 2025

Non-human primates (NHPs), such as macaques and cynomolgus monkeys, have long served as a cornerstone in preclinical drug development due to their close genetic, anatomical and physiological resemblance to humans. Food and Drug Administration (FDA). Ncardia, 2024. Bailey J, et al. Experimental Biology and Medicine.

Drug Research

Alta Sciences

MARCH 4, 2025

Over time, this group of professionals evolved and grew, having regular stakeholder interactions with the FDA and Controlled Substances staff to discuss requirements for drug developers. I have spent the better part of my career working to make drugs safer. About the Author Beatrice Setnik, PhD, Chief Scientific Officer.

Clinical Trials

SugarCone Biotech

JUNE 19, 2025

The results were remarkable for this very sick patient population, with a median OS of 14 months at the dose of 10 mg given every 2 weeks: The data supported FDA approval, in May 2024, of tarlatamab for refractory ES-SCLC. The Next Wave: Targeting B7H3 – a drug development tsunami in the making? An awesome space to watch.

Therapies

Alta Sciences

NOVEMBER 15, 2024

4 Essential Topics to Cover in Your First CRO Meeting pmjackson Fri, 11/15/2024 - 19:22 Starting a partnership with a contract research organization (CRO) is a sometimes intimidating—yet exciting—first step in your drug development journey. Image thumbnail_Blog_Chad and Lisa_v3.jpg

Drug Development

Perficient: Drug Development

NOVEMBER 20, 2024

To enable this feature, include the header anthropic-beta: prompt-caching-2024-07-31 in your API calls, as prompt caching is currently in beta. For example, you might include the entire text of a book in your prompt and cache it, allowing you to ask multiple questions about the text without reprocessing it each time.

Engineering

The Pharma Data

JUNE 13, 2025

Startups that become participants in this new acceleration program will be able to reside at SakuLab™-Tsukuba, collaborate alongside their peers, and tap into the expertise and guidance offered by Astellas’ team of drug-development experts.

Research

Alta Sciences

NOVEMBER 13, 2024

Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services pmjackson Wed, 11/13/2024 - 14:50 Greater Montréal, Québec, 11/13, 2024 — Altasciences , a trusted drug development research partner for over 30 years, continues its commitment to providing world-class bioanalytical services.

Clinical Pharmacology

Drug Target Review

APRIL 7, 2025

GPCRs are critical targets for drug development due to their involvement in numerous disease pathologies, with many medications working by either activating or inhibiting these receptors. 2022) Why 90% of clinical drug development fails and how to improve it?, Available at: [link] (Accessed: 23 September 2024).

Fragment Screening

The Premier Consulting Blog

OCTOBER 30, 2024

As outlined earlier in this blog, innovative manufacturing techniques are key for producing superior quality medicine, as improvement in quality manufacturing can limit drug shortages due to quality-related issues. CDER-D2S07-Prabhakara, REdI Annual Conference 2024, The Advanced Manufacturing Technologies Designation Program.

FDA

Alta Sciences

DECEMBER 31, 2024

In Issue 7 of The Altascientist , we delve into these factors, the importance of drug interaction studies, and how to limit adverse effects and maximize treatment response. These interactions must be identified during the development process as part of the assessment of the drugs risks and benefits.

Therapies

Drug Target Review

AUGUST 8, 2025

This is reflected in over eight hundred new bispecific assets identified in the sector through 2024. 3 As these therapies evolve, so too must the tools and processes used to develop them. 2024 Bispecific Beacon landscape review [Internet]. A single-format approach is unlikely to be sufficient in the long term. Bispecific Beacon.

Engineering

BioPharma Drive: Drug Pricing

JULY 14, 2025

The company, which restructured in 2024 , is counting on these and other drugs in late-stage development to help improve growth in the years ahead. Recommended Reading Investors are waking up to Centessa’s sleepiness drug By Jacob Bell • Sept. 10, 2024 Psychiatry drugs finally have pharma’s attention.

Drugs

New Drug Approvals

APRIL 2, 2025

This action and the agencys designations to expedite the drugs development and review underscore FDAs commitment to approving safe and effective alternatives to opioids for pain management. 10] An alternative to opioids, it is the first pain medication to be approved by the Food and Drug Administration in two decades. [10]

FDA

Codon

NOVEMBER 3, 2024

As an undergraduate biology student, I spent some time in a TB lab working on antibiotic resistance — a growing concern for drug developers. We have controlled other bacterial pests once common in the developing world through the top-down work of health agencies and drug developers and the bottom-up efforts of local volunteers.

Vaccine

Drug Target Review

JUNE 5, 2025

Studies presented at the American Society of Hematology 2024 Annual Meeting have predicted that patients receiving regular aRBCX would save up to $100,000 per patient lifetime to the healthcare system compared to other transfusion modalities, while increasing quality of life. 2024 Sep 10;2:101875. Blood Adv (2024) 8 (4): 10181029.

Disease

Broad Institute

NOVEMBER 21, 2024

Researchers identify source of a brain cancer’s deadly transformation By Corie Lok November 21, 2024 Breadcrumb Home Researchers identify source of a brain cancer’s deadly transformation Slow-growing glioma tumors become more aggressive when their cells shift identities and acquire new genetic mutations. Online November 21, 2024.

Research

BioPharma Drive: Drug Pricing

JUNE 11, 2025

And though Roche and Bristol Myers acquired both their medicines in high-priced acquisitions, they haven’t yielded significant sales: Rozlytrek generated about 134 million Swiss francs in 2024 , while Augtyro pulled in just $38 million. Sanofi’s $9.1 Sanofi’s $9.1

FDA

SugarCone Biotech

JULY 6, 2025

It follows that HER3-targeting therapies have emerged as a class of anti-cancer treatments designed to treat various tumors that have developed resistance to EGFR or HER2-directed therapies or have emerged due to a NRG1 gene fusion. This is an active drug development landscape with a lot of recent news.

Drug Development

New Drug Approvals

AUGUST 7, 2025

PATENT example 93 [US20170334929A1] SYN European Journal of Medicinal Chemistry 265 (2024) 116124 Repotrectinib (Augtyro) Repotrectinib, developed by Turning Point Therapeutics, Inc., These mutations restrict the ability of drugs to bind to their targets, ultimately resulting in the advancement of tumors. 14 November 2024.

FDA

Perficient: Drug Development

JULY 17, 2025

O ur award-winning Growth for Everyone initiative provide s a wide range of professional development programs, including Consultant Curriculum , Leading With Impact , and Learning to Lead. In 2024, more than 100 Perficient colleagues served as mentors across seven AI B ootcamps, championing a more equitable digital future.

Engineering

Conversations in Drug Development Trends

NOVEMBER 5, 2024

In preparation for World Orphan Drug Congress Europe, we interviewed Nathan Chadwick, Senior Director, Therapeutic Strategy Lead, Rare Disease, and Derek Ansel, MS, LCGC, Vice President, Therapeutic Strategy Lead, Rare Disease, to hear their insights into the current progress in rare disease research and their hopes for 2025.

Disease

The Pharma Data

JULY 3, 2025

Dr. Saward, who joined Synedgen in 2024 as Chief Scientific Officer (CSO), will retain her CSO responsibilities while stepping into her expanded leadership role. Kenton Gregory as CMO Amid Strategic Growth Synedgen, Inc., The company has promoted Dr. Laura Saward, Ph.D., to President and Chief Executive Officer.

FDA Approval

BioPharma Drive: Drug Pricing

JULY 18, 2025

In his 2024 book Blind Spots — and again during Thursday’s panel — he questioned the evidence showing higher cancer risk and argued that MHT may actually prevent cardiovascular and cognitive diseases. An arm of the trial arm involving use of estrogen only was also stopped early in 2004 due to an apparent increased risk of stroke.

Therapies

BioPharma Drive: Drug Pricing

JULY 10, 2025

But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes. 4, 2024 Adeline Kon / BioPharma Dive/BioPharma Dive Deep Dive // Patent thickets Drug patents protect pharma profits. By Jonathan Gardner • Sept. Track when they’ll expire.

Drugs

Perficient: Drug Development

FEBRUARY 12, 2025

You May Also Enjoy: Getting Started On Embedded Finance Payments Trend #6: Crypto and Payments Intersect In 2024, crypto made a strong comeback, with Bitcoin surpassing $100,000 , driven by its integration into exchange-traded funds.

Compliance

Drug Target Review

MAY 5, 2025

While another pandemic has not reached our doorstep at least not yet our sense of urgency and creativity should be the fuel for reimagining clinical development processes. The staggering average cost of bringing a drug to market (more than $1 billion) is accompanied by a dismal success rate of justfive to seven percent.

Clinical Development

Perficient: Drug Development

MAY 21, 2025

H e re are a few recent examples of how Perficient and our colleagues are making a difference for our communities : In 2024, Perficient and our global colleagues collectively donated more than 11,000 pounds of food and 46,000 meals during Hunger Action Month. In 2024, we hosted AI Bootcamps in seven cities for 114 students.

Marketing

PPD

APRIL 14, 2025

Participant fatigue in GLP-1 clinical trials The success of GLP-1 drugs in SELECT and other trials has biotech and biopharma companies racing to find which indications respond well to similar treatment. As of mid-2024, this includes at least 650 Phase I-IV trials, with about 430 of those already ongoing.

Clinical Trials

FDA Law Blog: Drug Discovery

APRIL 20, 2025

Patient Listening Sessions and Patient-Focused Drug Development meetings) to more systematically involve patients, allowing them to educate all stakeholders about their lived experiences and treatment needs. Her comments should reassure patients and product developers that the progress made with the launch of the Hub is maintained.

FDA